{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"106"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"333"}],"units":"Participants"}],"title":"TSH > ULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"327"},{"groupId":"OG001","value":"331"}],"units":"Participants"}],"title":"TSH > ULN WITH TSH <= ULN AT BASELINE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"318"},{"groupId":"OG001","value":"322"}],"units":"Participants"}],"title":"TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"318"},{"groupId":"OG001","value":"322"}],"units":"Participants"}],"title":"TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"318"},{"groupId":"OG001","value":"322"}],"units":"Participants"}],"title":"TSH > ULN WITH FT3/FT4 TEST MISSING"},{"categories":[{"measurements":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"333"}],"units":"Participants"}],"title":"TSH < LLN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"327"},{"groupId":"OG001","value":"331"}],"units":"Participants"}],"title":"TSH <LLN WITH TSH >= LLN AT BASELINE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"318"},{"groupId":"OG001","value":"322"}],"units":"Participants"}],"title":"TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"318"},{"groupId":"OG001","value":"322"}],"units":"Participants"}],"title":"TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"318"},{"groupId":"OG001","value":"322"}],"units":"Participants"}],"title":"TSH < LLN WITH FT3/FT4 TEST MISSING"}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"333"}],"units":"Participants"}],"description":"The number of participants with clinical laboratory test abnormalities in specific thyroid tests based on US conventional units.","groups":[{"description":"Participants receive BMS-986213 (IV fixed-dose combination relatlimab/nivolumab at a 1:3 ratio) every 4 weeks (Q4W).\n\nFor adults, dosing is relatlimab 160 mg/nivolumab 480 mg. Adolescents ≥ 40 kg will receive adult dosing; for adolescents \\< 40 kg, dosing is relatlimab 2 mg/kg/nivolumab 6 mg/kg.","id":"OG000","title":"Arm A: Relatlimab + Nivolumab"},{"description":"Participants receive Nivolumab IV monotherapy every 4 weeks (Q4W).\n\nDosing for adults is 480 mg. Adolescents ≥ 40 kg will receive adult dosing; for adolescents \\< 40 kg, dosing is 6 mg/kg.","id":"OG001","title":"Arm B: Nivolumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants with at least one on-treatment measurement of the corresponding laboratory parameter.","reportingStatus":"POSTED","timeFrame":"From first dose to 30 days after last dose of study therapy (up to approximately 33 months)","title":"The Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}